Moderna, Inc. (MRNA): Free Cash Flow
-$2.06B
Year ended 2025-12-31
-$1.24B
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$2.06B | n/m | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | -$4.05B | n/m | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | -$3.83B | n/m | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $4.58B | -65.6% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $13.34B | +580.8% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $1.96B | n/m | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | -$491.00M | n/c | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | -$436.63M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$389.88M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $33.59M | n/a | 2019-03-13, From 2016-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | -$2.06B | n/m |
| Qiagen N.V. (QGEN) | 2025-12-31 | $453.28M | -10.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $875.84M | +30.4% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $644.59M | +37.6% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $748.70M | +34.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $263.22M | +2.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $344.90M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $93.90M | -37.3% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $27.82M | -74.8% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗